RMTG
Regenerative Medical Technology Group Inc.$0.0400 +0.00 (+0.00%)
Oct 26 4:00 PM ET · prev $0.0400
1 year
−22.0%
from $0.0513 · Oct 28
30 days
−31.5%
from $0.0584
52-week range
$0.0189–0.1200
−67% from high · low Jun 8
Avg volume 20D
26.2K
Oct 15 spike 88.0K
Short interest
175
−98.0%
Days to cover
1.0
at average volume
Filing reports
1
analyzed by SecBot
SecBot read MIXED 1 report · 90 days
Balance 0 bearish · 0 bullish · 1 neutral oldest → newest, height = score
Avg score ·High conf. 1/1
Price
Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.
No data for this timeframe.
- X Jul 31 Short interest falls 96.5% to 100
- X Aug 14 Short interest jumps 8574.0% to 8.7K
- E Sep 2 Trial readout: T-90d Trial Readout: d-MAPPS (Phase 2)
- E Sep 10 Trial readout: T-90d Trial Readout: d-MAPPS (Phase 2)
- E Sep 14 Trial readout: T-90d Trial Readout: d-MAPPS (Phase 2)
- X Oct 15 Short interest falls 98.0% to 175
Signal stack
Where each data set points today.
- Short sellersCOVERING
Short interest −98.0% to 175 shares. 1.0 days to cover.
- TrendDOWNTREND
40% below its 50-day average.
- SocialQUIET
No Reddit mentions this week. Last mention Oct 16.
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 13, 2026 Clinical trial readout
Aug 25, 2026 SEC T-90d Trial Readout: d-MAPPS (Phase 2)
Trial: Study of d-MAPPS™ Ophthalmic Solution, Safety, Tolerability, and Efficacy in the Treatment of
Regenerative Medical Technology Group Inc. (RMTG) filed an 8-K to furnish a transcript of an investor video call held…
8-K — Impact 2/10
Reddit
Recent posts
All social signals and their track recordsEarnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | — | — | — | $0.00 |
| Next Q | — | — | — | $0.00 |
| Current FY | — | — | — | $0.00 |
| Next FY | — | — | — | $0.00 |
Short side
FINRA· Oct 15, 2026175
shares short
-98.0%
vs prior settlement
1.0
days to cover
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Sep 13, 2026
Trial readout
T-90d Trial Readout: d-MAPPS (Phase 2)
Trial: Study of d-MAPPS™ Ophthalmic Solution, Safety, Tolerability, and Efficacy in the Treatment of Chronic Ocular Graft-Versus-Host Disease…
Sep 10, 2026
Trial readout
T-90d Trial Readout: d-MAPPS (Phase 2)
Trial: Study of d-MAPPS™ Ophthalmic Solution, Safety, Tolerability, and Efficacy in the Treatment of Chronic Ocular Graft-Versus-Host Disease…
Sep 1, 2026
Trial readout
T-90d Trial Readout: d-MAPPS (Phase 2)
Trial: Study of d-MAPPS™ Ophthalmic Solution, Safety, Tolerability, and Efficacy in the Treatment of Chronic Ocular Graft-Versus-Host Disease…
SecBot reports
1 filing · 0 bullish · 0 bearish · 1 neutralAll RMTG filing & press-release reports (1)
- 8-K reportAug 25, 2026